About Immunocine Cancer Center
Immunocine: Pioneering Personalized Immunotherapy
Established in 2021, the Immunocine Cancer Center is nestled in the serene landscapes of Cancun, Mexico.
Its founding mission was clear: provide groundbreaking immunotherapy to those unable to access ongoing FDA Clinical Trials.
The genesis of Immunocine’s approach traces back to 2006 within the prestigious confines of the Houston Medical Center. Dr. Matthew Halpert and a team of cancer immunologists focused on the development of double-loaded Dendritic Cell Treatment, which has since demonstrated its effectiveness both in meticulous laboratory studies and heartening real-world patient stories.
With a track record of over 150 patients spanning 25 diverse cancer types, Immunocine offers new hope in the battle against cancer.
Immunocine’s treatment is currently going through clinical trials in Texas for pancreatic cancer and brain cancer. However, as only a fraction of patients are admitted to those clinical trials, many patients are left without access to these emerging therapies. This gap in treatment accessibility led to the creation of Immunocine in Cancun, Mexico, designed to provide critical therapies to those unable to participate in clinical trials in the United States.
Treatment Eligibility Requirements
Solid Tumors
The clinic currently treats only patients with solid tumors that can be biopsied.
Ability to Travel
Treatment is administered exclusively at the clinic’s facilities in Cancun. Patients unable to travel due to medical conditions or other factors will not be eligible for treatment.
Stable Immune System
A stable, functioning immune system is essential for the success of immunotherapy. Patients with immune deficiencies must restore normal activity before qualifying for treatment.
6-Week Treatment
The treatment protocol requires three sessions over six weeks. Patients can either stay in Cancun for the full duration or visit twice for two-week stays.
Why Choose Cancun, Mexico?
Cancun was selected for Immunocine not only for its geographic and aesthetic appeal but also for its strategic importance in offering accessible cancer treatments. This decision acknowledges the challenges associated with the FDA approval process and aims to provide an immediate solution for those in need. Moreover, Cancun’s recognition as a center for medical tourism, with advanced healthcare facilities, makes it an ideal location for such an innovative clinic.
For those at the crossroads of cancer care, searching either for a final ray of hope or the very forefront of immunotherapy, Immunocine stands as a dedicated partner, combining scientific rigor with compassionate care.
Spotlight
Elizabeth's Stage 4 Ovarian Healing Journey
Witness the extraordinary story of Babette, a stage 4 ovarian cancer warrior, as she embraces a groundbreaking journey with Immunocine clinic. Follow her remarkable path to remission filled with hope, innovation, and relentless spirit. Read more>>
Contact the Clinic
Take a Look
Meet the Doctors
Dr. Luis Ferbeyre, MD Chief Medical Officer & Oncologist
Dr. Luis Ferbeyre earned his Medical Degree from the Medical University of Havana. His early work in oncology focused on Mixed Tumors of the Salivary Glands. Subsequently, he studied Cervicofacial Cancer at the University of Paris and furthered his expertise in Head and Neck Cancer at the National Institute of Oncology and Radiology.
In addition to his specialized studies, Dr. Ferbeyre has contributed to research on the Genetic and Molecular Basis of Cancer and delved into Reconstructive Oncological Surgery for the Head and Neck. He has 31 peer-reviewed articles to his name and has been actively involved in multiple clinical trials.
Professionally, Dr. Ferbeyre is affiliated with the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology.
Dr. Matt Halpert, CEO
Dr. Matthew Halpert earned his doctorate at the University of Alabama-Birmingham (UAB) and then spent 10 years at Baylor College of Medicine in Houston as a Cancer Immunologist. During his research, Dr. Halpert published research in some of the most prestigious peer-reviewed journals, has been cited over 300 hundred times, and became one of the leading experts in regard to cutting-edge cancer immunotherapy.
Additionally, he has founded a cancer-focused charity called Cancer Cures 4 Kids and Diakonos Research, which is currently studying its revolutionary Dendritic Cell Treatment in multiple FDA clinical trials.
In 2021, Dr. Halpert left Baylor College of Medicine to found the Immunocine Cancer Center, which leverages the Dendritic Cell Treatment currently being studied by the FDA. His singular goal in this effort is to provide this revolutionary cancer immunotherapy to patients that cannot wait for treatment.
Conditions Treated
- All types of solid Cancers – Using a novel process replicating a viral infection, Immunocine’s unique treatment initiates a rapid and aggressive immune response against cancer cells throughout the body